

To  
The Manager  
BSE Limited  
P. J. Towers, Dalal Street,  
Mumbai – 400001.

Date: 10.02.2024

Dear Sir/Madam,

**Sub: Outcome of board meeting under regulation 30 read with 33 (3) (c) of SEBI (Listing Obligations and Disclosure requirements) regulations, 2015**

**Unit: Vista Pharmaceuticals Limited (BSE Scrip Code: 524711).**

With reference to the subject cited, this is to inform the Exchange that meeting of the Board of Directors of M/s. Vista Pharmaceuticals Limited held on Saturday, the 10<sup>th</sup> day of February, 2024, at 4:30 P.M at the Registered office of the Company were duly considered and approved by the board:

1. Un-Audited financial results for the quarter ended 31.12.2023.
2. Limited Review Report for quarter ended 31.12.2023.
3. Appointment of Mr. Barkha Jain as a Company Secretary and Compliance officer of the Company.
4. Convene Extra Ordinary General Meeting of the company to be held through Video Conferencing (“VC”)/Other Audio-Visual Means (“OAVM”) on Wednesday, the 6th day of March, 2024 at 11:00 A.M. to seek approval of the shareholders for appointment of Independent Directors.

The meeting of the Board of Directors commenced at 4.30. P.M (IST) and concluded at 5.30 P.M (IST)

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,  
For Vista Pharmaceuticals Limited

 

Dhnananjaya Alli  
Whole Time Director  
DIN 00610909

VISTA PHARMACEUTICALS LIMITED							(Rs in Lakhs)
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER III AND 9 MONTHS ENDED 31ST DECEMBER, 2023							
Sr.No	Particulars	Quarter ended			Year to date figures		Previous Year ended 31-03-2023
		3 Months ended 31-12-2023	Corresponding 3 months ended in previous year 31-12-2022	Preceding 3 months ended 30-09-2023	For current period 9 Months ended 31-12-2023	For previous period 9 Months ended 31-12-2022	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
<b>I</b>	<b>Revenue from Operations</b>	170.45	-	346.98	715.53	-	100.37
<b>II</b>	<b>Other Income</b>	2.41	-	7.97	23.58	-	39.94
<b>III</b>	<b>Total Revenue (I+II)</b>	<b>172.86</b>	<b>-</b>	<b>354.94</b>	<b>739.11</b>	<b>-</b>	<b>140.31</b>
<b>IV</b>	<b>Expenses</b>						
	Cost of Material Consumed	221.24	-	311.29	738.90	-	282.84
	Changes in Inventories	-	-	9.46	-	-	-
	Employee benefits expense	45.49	18.20	44.52	131.74	25.90	50.87
	Finance Cost	29.70	39.66	31.82	94.18	89.14	121.35
	Depreciation and Amortisation expense	18.34	15.40	18.24	53.92	46.20	61.76
	Other Expenses	76.97	15.28	74.08	202.61	42.58	211.12
	Prior Period Expenses	1.24	-	24.41	25.65	-	-
	<b>Total Expenses</b>	<b>392.98</b>	<b>88.54</b>	<b>513.82</b>	<b>1,247.01</b>	<b>203.82</b>	<b>727.94</b>
<b>V</b>	<b>Profit/(Loss) from before Exceptional Items and tax (I-IV)</b>	<b>(220.12)</b>	<b>(88.54)</b>	<b>(158.88)</b>	<b>(507.90)</b>	<b>(203.82)</b>	<b>(587.63)</b>
<b>VI</b>	<b>Exceptional Items</b>	-	-	-	-	-	-
<b>VII</b>	<b>Profit/(Loss) before tax (V-VI)</b>	<b>(220.12)</b>	<b>(88.54)</b>	<b>(158.88)</b>	<b>(507.90)</b>	<b>(203.82)</b>	<b>(587.63)</b>
<b>VIII</b>	<b>Tax Expense:</b>	-	-	-	-	-	-
	Current /Previous Year Tax	-	-	-	-	-	(105.26)
	Deferred Tax	(57.23)	7.22	43.05	(47.63)	(25.04)	83.83
<b>IX</b>	<b>Profit/ (Loss) for the period from Continuing operations (VII-VIII)</b>	<b>(162.89)</b>	<b>(95.76)</b>	<b>(201.93)</b>	<b>(460.27)</b>	<b>(178.78)</b>	<b>(566.20)</b>
<b>X</b>	<b>Profit/ (Loss) from discontinuing operations</b>	-	-	-	-	-	-
<b>XI</b>	<b>Tax Expense of discontinuing operations</b>	-	-	-	-	-	-
<b>XII</b>	<b>Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)</b>	-	-	-	-	-	-
<b>XIII</b>	<b>Profit/ (Loss) for the period (IX+XII)</b>	<b>(162.89)</b>	<b>(95.76)</b>	<b>(201.93)</b>	<b>(460.27)</b>	<b>(178.78)</b>	<b>(566.20)</b>

<b>XIV</b>	<b>Other Comprehensive Income</b>						
	<b>A) (i) Items that will not be reclassified to profit or loss</b>						
	<b>(ii) Income Tax related to items that will not be reclassified to profit or loss</b>	0.14	-	0.31	0.57	-	-
	<b>B) (i) Items that will be reclassified to profit or loss</b>	-	(2.67)	-	-	(18.47)	(0.25)
	<b>(ii) Income Tax relating to items that will be reclassified to profit or loss</b>	-	-	-	-	-	-
<b>XV</b>	<b>Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)</b>	(162.75)	(98.43)	(201.62)	(459.70)	(197.25)	(566.45)
<b>XVI</b>	<b>Earnings Per Equity Share (For Continuing Operations) (Face Value INR 2/- each)</b>						
	<b>1) Basic</b>	(0.33)		(0.46)	(1.05)	(0.54)	(1.54)
	<b>2) Diluted</b>	(0.26)	(0.27)	(0.15)	(0.34)	(0.75)	(0.90)
<b>XVII</b>	<b>Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 2/- each)</b>						
	<b>1) Basic</b>	-	-	-	-	-	-
	<b>2) Diluted</b>	-	-	-	-	-	-
<b>XVIII</b>	<b>Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 2/- each)</b>						
	<b>1) Basic</b>	(0.33)	(0.27)	(0.46)	(1.05)	(0.54)	(1.54)
	<b>2) Diluted</b>	(0.26)	(0.15)	(0.34)	(0.75)	(0.31)	(0.90)
<b>XIX</b>	<b>Paid Up Equity Share Capital (Face Value of INR 2/- per share)</b>	937.96	735.88	883.83	937.96	735.88	751.13

**Notes:**

- 1.The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the companies (Indian Accounting standards) Rules, 2015 as amended by the companies (Indian Accounting standards) (Amendment) rules,2016.
- 2.The above Financial results recommended by the Audit Committee are considered and approved by the Board of Directors at their meeting held on 10th February , 2024
- 3.The Statutory Auditors of the Company have carried out "Limited Review" of the above unaudited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.
4. Total turnover for the current quarter reported 170.45 lakhs compared to NIL turnover for the corresponding quarter of the previous year.
5. The Loss before tax for the current quarter is Rs.220.12 Lakhs compared to Loss Before tax of Rs. 88.54 Lakhs for the corresponding quarter of the previous year.
- 6.The Entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products., Hence, segmental reporting as per IND AS-108 is not made.
- 7.The results for the quarter ended 31st December 2023 are also available on the bomabay stock exchange website, the National Stock exchange website and on the Company's website.
8. The company has issued 267.58 lakhs convertible Share Warrants on 14/10/2022 on preferential basis at an Issue price of Rs. 10/- (Rupees ten Only) per Convertible warrant which includes premium Rs. 8/- per warrant. The Share warrants are convertible into each equity share within period 18 months from the date of allotment of warrants.
9. The 27.07 lakhs Share warrants are converted to equity shares during the current quarter and total 93.42 lakhs Share Warrants are converted to equity shares till end of the quarter during the year.
10. The Share warrants issued are considered for calculation of Diluted EPS during the period.
- 11.Figures for the previous periods /year have been regrouped/reclassified wherever necessary.

**Place:Hyderabad**

**Date: 10/02/2024**

**For Vista Pharmaceuticals Limited**



**Dhananjaya Ali**  
**Whole Time Director**

**DIN: 00610909**



**Independent Auditor’s Review Report on unaudited Quarterly Financial results of VISTA PHARMACEUTICALS LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To,  
The Board of Directors,  
Vista Pharmaceuticals Limited.

1. We have reviewed the accompanying statement of unaudited financial results of Vista Pharmaceuticals Limited (“the Company”) for the quarter ended December 31, 2023 and year to date results for the period October 1st, 2023 to December 31, 2023 (“the Statement”) attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“the Regulation”)
2. This Statement, which is the responsibility of the company’s Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 “Interim Financial Reporting”, prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognised accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We Conducted our review of the statement in accordance with the Standard of Review engagement (SRE) 2410, “Review of Interim Financial Information Performed by the independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to

obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit Opinion.

Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For A.M REDDY & D.R REDDY**

Chartered Accountants

Firms Registration No: 009068S



D.Rama Krishna Reddy

Partner

Membership No. 209211

UDIN: 24209211BKHHRC1571

Place: Hyderabad

Date: February 10, 2024

